Baseline Predictors for Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration

Published

2022

Audience

Therapeutic Area

Content Type

AI Generated Summary*

Forty-five treatment-naive eyes with neovascular age-related macular degeneration were followed for 12 months on an aflibercept treat-and-extend regimen to look for baseline signs of subretinal fibrosis. Fibrosis at month 12 was judged using color fundus photography, fluorescein angiography and polarization-sensitive OCT, with microperimetry settling one discordant case. Eight eyes (18%) developed fibrosis; these had worse baseline acuity (median 54 versus 74 ETDRS letters, p=0.001), and every one showed intraretinal fluid (versus 51%, p=0.014) and subretinal hyperreflective material (versus 54%, p=0.017). A subretinal lesion component, type 2 or mixed, was present in 88% of fibrotic eyes versus 8% of the rest. Among the 33 eyes with quantifiable angiography lesions, no vascular metric differed significantly, though this exploratory sample was small.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.

At a glance

Authors
Philipp K. Roberts; Markus Schranz; Alice Motschi; Sylvia Desissaire; Valentin Hacker; Michael Pircher; Stefan Sacu; Wolf Buehl; Christoph K. Hitzenberger; Ursula M. Schmidt-Erfurth
Publication
Scientific Reports
Keywords
Angiogenesis Inhibitors, Fibrosis, Fluorescein Angiography
Year
2022
View primary source

This is the evidence

See where we take it next

Join the Network